# Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma

> **NCT02148913** · PHASE1 · COMPLETED · sponsor: **Corewell Health West** · enrollment: 18 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Cohort 1: Carfilzomib 15 mg/m2
- **DRUG:** Cohort 2: Carfilzomib 20 mg/m2
- **DRUG:** Cohort 2b: Carfilzomib 20 mg/m2
- **DRUG:** Cohort 3b: Carfilzomib 27 mg/m2

## Key facts

- **NCT ID:** NCT02148913
- **Lead sponsor:** Corewell Health West
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02148913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02148913, "Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02148913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*